Jeffrey S. Weber, MD, PhD, NYU Langone Health

Jeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma.

Jeffrey S. Weber, MD, PhD, discusses the use of circulating-tumor DNA dynamics when guiding treatment decision-making in melanoma, according to data from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial.

Jeffrey S. Weber, MD, PhD, discusses findings from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial of mRNA-4157 in combination with pembrolizumab in resected high-risk melanoma.

Jeffrey S. Weber, MD, PhD, discusses unmet needs in ocular and mucosal melanoma.